Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05707390 · ClinicalTrials.gov registry record · Phase 1
A Study of Mezigdomide in Healthy Participants and Participants With Hepatic Impairment
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT05707390 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 32 participants.
The verdict
NCT05707390, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
The aim of this study is to measure the concentration levels of mezigdomide in the blood of participants with mild, moderate, and severe hepatic impairment, and in matched healthy control participants with normal hepatic function.
Interventions
- DRUG Mezigdomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2023-02-20 |
| Est. Completion | 2023-09-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05707390
The ClinicalTrials.gov registry entry for NCT05707390 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Mezigdomide is the first listed.
NCT05707390 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05707390 about?
NCT05707390 is a clinical study titled "A Study of Mezigdomide in Healthy Participants and Participants With Hepatic Impairment". The aim of this study is to measure the concentration levels of mezigdomide in the blood of participants with mild, moderate, and severe hepatic impairment, and in matched healthy control participants with normal hepatic function.
What is the current status of trial NCT05707390?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2023-02-20. Estimated completion is 2023-09-13.
What interventions are being tested in trial NCT05707390?
The interventions under investigation include: Mezigdomide (DRUG).
Who is sponsoring clinical trial NCT05707390?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.